Core Viewpoint - The revocation of the exclusive distribution rights for AestheFill (童颜针) by Regen has led to significant turmoil for *ST Suwu, resulting in a sharp decline in its stock price and potential legal battles for compensation [1] Group 1: Company Actions - On July 18, Regen sent a termination letter to Dato Medical, revoking its exclusive distribution rights for AestheFill in China [1] - In response, *ST Suwu announced on August 11 that its subsidiary Dato Medical has initiated arbitration against Regen for breach of contract, seeking initial compensation of 1.6 billion RMB [1] - *ST Suwu issued a strong statement condemning the actions of Aimeike, describing them as "capital bullying" and claiming that the situation has jeopardized the survival of the company and its subsidiary [1] Group 2: Financial Impact - The stock price of *ST Suwu experienced consecutive trading halts following the announcement of the revocation of distribution rights [1] - The company claims that over 80,000 small and medium investors have been severely affected, along with thousands of employees and numerous partner institutions facing significant losses [1]
爱美客撤销童颜针代理权,*ST苏吴索赔16亿